- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02747485
Impact of Diffuse Myocardial Fibrosis on the Ventricular Function in Regurgitant Left-Sided Valve Heart Diseases ( The DIFFUsE Study) (DIFFUsE)
Impact of Diffuse Myocardial Fibrosis on the Ventricular Function in Regurgitant Left-Sided Valve Heart Diseases " The DIFFUsE Study "
New strategies are needed to early detect myocardial involvement in these diseases. Histological studies showed that diffuse fibrosis and cardiomyocyte hypertrophy precede the LV remodelling (dilatation) observed by cardiac imaging. Quantification of LV diffuse myocardial fibrosis using magnetic resonance imaging (MRI) could reach this goal. Recently, contrast enhanced cardiac MRI has been used to measure the extracellular volume fraction (ECV) of the myocardium, and it has been able to detect diffuse myocardial fibrosis. In diseases in which increased collagen deposition enlarges the extra-cellular space, the ECV can act as a fibrosis index. ECV is correlated with the amount of fibrosis measured by histology. Left ventricular overloads induced by regurgitant VHD result in cardiomyocyte hypertrophy and diffuse fibrosis. Other methods can be used to estimate the degree of myocardial fibrosis such as the serum level of galectine-3 or ST2. Moreover, although the pathophysiological mechanisms leading to the occurrence of myocardial fibrosis differ in patients with various cardiac diseases, the cellular effectors of fibrotic remodelling are common and involve similar signalling pathways. At the cellular level, key progression of ventricular hypertrophy is associated with increased cardiomyocytes apoptosis and fibrosis, suggesting that these two processes are responsible for the transition.
To our knowledge, no study has analysed the impact of the rate of myocardial diffuse fibrosis, non-invasively estimated by ECV, in the risk of LV dysfunction during MR and AR, especially after surgery. The measurement of ECV could become an important tool for risk stratification in left-sided regurgitant VHD. Thus, it would provide an early marker of LV myocardial involvement before the occurrence of global remodeling, might help physicians in surgical decision, and would improve prognosis. This is an innovative original project because it uses modern imaging modalities to answer to a crucial question. The clinical implications would be important because this work would modify the international surgical indications of MR and AR in order to finally improve the prognosis of patients with this frequent heart disease. Moreover, investigators will analyze the genetic factors that can influence the myocardial reaction resulting from these regurgitations, which will improve the quality of this work and offer new future perspectives.
Investigators hypothesize that the ECV measurement could be used as an early predictor of LV dysfunction in the left-sided valve regurgitations.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Bouche DU Rhone
-
Marseille, Bouche DU Rhone, France, 13354
- Recruiting
- Assistance Publique Hopitaux de Marseille
-
Contact:
- THUNY FRANCK
- Email: franck.thuny@ap-hm.fr
-
Contact:
- AVIERINOS JEAN-FRANCOIS
- Email: jfavierinos@ap-hm.fr
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- All consecutive patients referred for organic MR and/or AR at least moderate to severe according to the ESC guidelines criteria⁴ will be eligible. The moderate to severe criteria will defined by echocardiography as followed:
- MR: an effective regurgitant orifice area (EOA) >30mm2 and/or a regurgitant volume (RV) >45mL
- AR: an EOA >20mm2 and/or a RV >45mL
Exclusion Criteria:
- Age < 18 years
- Pregnancy
- Impossibility to maintain a decubitus position
- Arrhythmia that do not allow an ECG synchronization during MRI
- Hemodynamic instability
- Indication of urgent surgery
- Known coronary artery disease
- Severe arterial hypertension
- Cardiomyopathy
- Claustrophobia
- Gadolinium intolerance
- Implantable medical devices that do allow to perform MRI
- Severe renal insufficiency with clearance <35 mL/min
- Vulnerable patients
- Acute infective endocarditis
- Aortic dissection
- Moderate or severe mitral stenosis (mitral area <1.5cm2/m2)
- Moderate or severe aortic stenosis (aortic area <0.8cm2/m2, or Vmax>3m/s, or mean gradient>30mmHg)
- Previous cardiac surgery
Study Plan
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: organic left-sided regurgitant valve
|
Serum levels of biomarkers of myocardial fibrosis (galectine-3 and ST2) will be measured
extract DNA to look for genomic mutations associated with the disease.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
the rate of diffuse myocardial fibrosis
Time Frame: 6 months
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Correlations between ECV and the global longitudinal strain and the serum level of Galectin-3 and ST2
Time Frame: 42 months
|
42 months
|
Correlations between ECV changes and genetic factors
Time Frame: 42 months
|
42 months
|
correlations between ECV and the severity of the regurgitation
Time Frame: 42 months
|
42 months
|
correlation between ECV and the myocardial deformation quantified by speckle tracking echocardiography (2D Strain)
Time Frame: 42 months
|
42 months
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2016-11
- 2015-A00587-42 (OTHER: ansm)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Valve Heart Diseases
-
National Heart, Lung, and Blood Institute (NHLBI)WithdrawnHeart Failure | Aortic Valve Stenosis | Mitral Valve Regurgitation | Heart Valve Disease | Tricuspid Valve RegurgitationUnited States
-
Boston Children's HospitalRecruitingValve Disease, Heart | Valve Heart Disease | Valve Disease, AorticUnited States
-
Edwards LifesciencesActive, not recruitingHeart Failure | Mitral Valve Insufficiency | Mitral Valve Regurgitation | Mitral Valve DiseaseUnited States, Australia, Brazil
-
Medical College of WisconsinChildren's Hospital and Health System Foundation, WisconsinCompletedMitral Valve Regurgitation | Tricuspid Valve Regurgitation, Non-rheumaticUnited States
-
UMC UtrechtLeiden University Medical Center; The Interuniversity Cardiology Institute... and other collaboratorsTerminatedMitral Valve Insufficiency | Diseases of Mitral Valve | Heart; Disease, Mitral(Valve)Netherlands
-
Xijing HospitalRecruitingAortic Valve RegurgitationChina
-
Maria Cecilia HospitalRecruiting
-
Edwards LifesciencesRecruitingCardiovascular Diseases | Heart Failure | Heart Valve Diseases | Tricuspid Valve Regurgitation | Tricuspid Valve Insufficiency | Tricuspid Valve DiseaseUnited States, Germany
-
Synecor, LLCUnknownHeart Failure | Mitral Valve Insufficiency | Mitral Valve Regurgitation | Mitral Valve Disease
-
Assistance Publique Hopitaux De MarseilleSuspendedAortic Valve Regurgitation AcquiredFrance
Clinical Trials on Cardiac MRI
-
University of FloridaOcala Royal DamesActive, not recruitingBreast CancerUnited States
-
University of MichiganNational Heart, Lung, and Blood Institute (NHLBI); Nationwide Children's Hospital and other collaboratorsCompletedPulmonary Hypertension | Congenital Heart Disease | Pediatric Congenital Heart DiseaseUnited States
-
Imperial College LondonNational Institute for Health Research, United Kingdom; Imperial College Healthcare...WithdrawnMyocardial Fibrosis | Heart Failure | End Stage Renal Failure on Dialysis | Chronic Kidney Disease Stage V | Chronic Kidney Disease, Stage IV (Severe)United Kingdom
-
St. Jude Children's Research HospitalRecruitingSepsis | Acute Respiratory Distress Syndrome | Cardiovascular ShockUnited States
-
University Medical Center GoettingenNot yet recruitingTetralogy of Fallot | Congenital Heart DiseaseGermany
-
Cedars-Sinai Medical CenterRecruitingHealthyUnited States
-
Medical University of GrazEnrolling by invitationPulmonary Hypertension | Elevated Mean Pulmonary Arterial Pressure | Normal Mean Pulmonary Arterial PressureAustria
-
Cedars-Sinai Medical CenterNational Heart, Lung, and Blood Institute (NHLBI); University of Pittsburgh; University...Active, not recruitingCardiovascular DiseaseUnited States
-
University Hospital Birmingham NHS Foundation TrustUnknownTetralogy of FallotUnited Kingdom
-
University Hospital Birmingham NHS Foundation TrustUnknownCardiomyopathiesUnited Kingdom